Computational techniques in fragment based drug discovery.

Fragment based drug discovery is gaining acceptance as a complement to other more established techniques to identify leads and optimize drug candidates. In this review we illustrate areas where fragment based drug discovery has had an impact and point to some examples that show how fragment based analysis is being applied to new arenas. The traditional uses of computational methods in fragment based for lead discovery and optimization and for risk assessment are briefly summarized. The application of fragment analysis for the definition of bioisosteric replacements are discussed together with techniques to characterize the diversity of chemical libraries based on fragment distribution.

[1]  T. O'Brien,et al.  Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.

[2]  Thomas Sander,et al.  Toxicity-Indicating Structural Patterns , 2006, J. Chem. Inf. Model..

[3]  D. Ringe,et al.  Locating and characterizing binding sites on proteins , 1996, Nature Biotechnology.

[4]  J. Kazius,et al.  Derivation and validation of toxicophores for mutagenicity prediction. , 2005, Journal of medicinal chemistry.

[5]  Andrew R Leach,et al.  Fragment screening: an introduction. , 2006, Molecular bioSystems.

[6]  Matthew Clark,et al.  Generalized Fragment-Substructure Based Property Prediction Method , 2005, J. Chem. Inf. Model..

[7]  T. Blundell,et al.  Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. , 2006, Journal of medicinal chemistry.

[8]  Maurizio Pellecchia,et al.  Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox. , 2004, Chemistry & biology.

[9]  D. Erlanson.  Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.

[10]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[11]  P. Hajduk,et al.  SAR by NMR: putting the pieces together. , 2006, Molecular interventions.

[12]  Jordi Mestres,et al.  Exploring the active site of human factor Xa protein by NMR screening of small molecule probes. , 2003, Organic & biomolecular chemistry.

[13]  D. V. Von Hoff,et al.  Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach , 2006, Molecular Cancer Therapeutics.

[14]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[15]  G. Klopman,et al.  Searching for an Enhanced Predictive Tool for Mutagenicity , 2004, SAR and QSAR in environmental research.

[16]  Sarah L. Rodgers,et al.  Building a tree of knowledge: analysis of bitter molecules. , 2005, Chemical senses.

[17]  Dale E. Johnson,et al.  Computational toxicology: heading toward more relevance in drug discovery and development. , 2006, Current opinion in drug discovery & development.

[18]  Sandor Vajda,et al.  Characterization of protein-ligand interaction sites using experimental and computational methods. , 2006, Current opinion in drug discovery & development.

[19]  G. Bemis,et al.  A minimalist approach to fragment‐based ligand design using common rings and linkers: Application to kinase inhibitors , 2004, Proteins.

[20]  Thomas Steger-Hartmann,et al.  Computational prediction of the chromosome-damaging potential of chemicals. , 2006, Chemical research in toxicology.

[21]  Jeffrey W. Peng,et al.  Applications of SHAPES screening in drug discovery. , 2002, Combinatorial chemistry & high throughput screening.

[22]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[23]  Ola Engkvist,et al.  Prediction of CNS Activity of Compound Libraries Using Substructure Analysis , 2003, J. Chem. Inf. Comput. Sci..

[24]  Brian Dymock,et al.  Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets , 2004, J. Chem. Inf. Model..

[25]  Christian Rummey,et al.  In silico fragment-based discovery of DPP-IV S1 pocket binders. , 2006, Bioorganic & medicinal chemistry letters.

[26]  Daniel A Erlanson,et al.  Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly. , 2004, Current opinion in chemical biology.

[27]  Didier Rognan,et al.  Assessing the Scaffold Diversity of Screening Libraries , 2006, J. Chem. Inf. Model..

[28]  R. Powers,et al.  Design and characterization of a functional library for NMR screening against novel protein targets. , 2006, Combinatorial chemistry & high throughput screening.

[29]  Maurizio Pellecchia,et al.  Structure- and fragment-based approaches to protease inhibition. , 2006, Current topics in medicinal chemistry.

[30]  Thomas Bäck,et al.  Substructure Mining Using Elaborate Chemical Representation , 2006, J. Chem. Inf. Model..

[31]  Thomas Bäck,et al.  Mining a Chemical Database for Fragment Co-occurrence: Discovery of "Chemical Clichés" , 2006, J. Chem. Inf. Model..

[32]  Matthias Rarey,et al.  FlexNovo: Structure‐Based Searching in Large Fragment Spaces , 2006, ChemMedChem.

[33]  György M Keseru,et al.  Hit discovery and hit-to-lead approaches. , 2006, Drug discovery today.

[34]  Markus Schade,et al.  NMR fragment screening: Advantages and applications. , 2006, IDrugs : the investigational drugs journal.

[35]  John C. Dearden,et al.  In silico prediction of drug toxicity , 2003, J. Comput. Aided Mol. Des..

[36]  R. Cox,et al.  A Fragment‐Based Approach to Understanding Inhibition of 1‐Deoxy‐D‐Xylulose‐5‐Phosphate Reductoisomerase , 2005, Chembiochem : a European journal of chemical biology.

[37]  Hugo O Villar,et al.  Using NMR for ligand discovery and optimization. , 2004, Current opinion in chemical biology.

[38]  V. Sridhar,et al.  Substructure-Based Support Vector Machine Classifiers for Prediction of Adverse Effects in Diverse Classes of Drugs , 2006, J. Chem. Inf. Model..

[39]  Tom L Blundell,et al.  High-throughput X-ray crystallography for drug discovery. , 2004, Current opinion in pharmacology.

[40]  Gisbert Schneider,et al.  Flux (1): A Virtual Synthesis Scheme for Fragment-Based de Novo Design , 2006, J. Chem. Inf. Model..

[41]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[42]  P. Hajduk.  Fragment-based drug design: how big is too big? , 2006, Journal of medicinal chemistry.

[43]  Peter D J Grootenhuis,et al.  Predicting passive transport in silico--history, hype, hope. , 2003, Current topics in medicinal chemistry.

[44]  Kerim Babaoglu,et al.  Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.

[45]  Edward R Zartler,et al.  Fragonomics: fragment-based drug discovery. , 2005, Current opinion in chemical biology.

[46]  G. Bemis,et al.  BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease. , 2004, Journal of medicinal chemistry.

[47]  M Karplus,et al.  HOOK: A program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site , 1994, Proteins.

[48]  Hans-Joachim Böhm,et al.  LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads , 1992, J. Comput. Aided Mol. Des..

[49]  W. Delano.  Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.

[50]  Matthew Clark,et al.  Grand Canonical Monte Carlo Simulation of Ligand-Protein Binding , 2006, J. Chem. Inf. Model..

[51]  Marcel L Verdonk,et al.  Automated Protein–Ligand Crystallography for Structure‐Based Drug Design , 2006, ChemMedChem.

[52]  Hugo O. Villar,et al.  Substructural Analysis in Drug Discovery , 2007 .